Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Foxglove root (Digitalis spp.) contains potent cardiac glycosides—primarily digitoxin and digoxin—that inhibit Na+/K+-ATPase in cardiac myocytes, increasing contractile force and slowing heart rate, with established clinical use in heart failure and atrial fibrillation. Recent research has also identified novel pharmaceutical potential: a 2020 study on Digitalis cariensis root/aerial parts demonstrated significant antioxidant capacity and enzyme inhibitory effects against cholinesterases and tyrosinase, expanding foxglove's relevance beyond cardiology (PMID 32980793).
Reported Benefits (Provisional)
Origin & History
Foxglove Root (Digitalis purpurea) is a herbaceous plant native to temperate regions of Europe, Western Asia, and parts of North Africa. While historically significant, it is critically important to note that this plant is highly toxic and contains potent cardiac glycosides. It is not used in functional nutrition or dietary supplements due to its narrow therapeutic index and severe risk of adverse effects.
Research Narrative (Provisional)
Zengin et al. (2020) conducted a comprehensive network analysis and chemical characterization of Digitalis cariensis, demonstrating notable antioxidant and enzyme inhibitory effects (against acetylcholinesterase, butyrylcholinesterase, tyrosinase, α-amylase, and α-glucosidase), positioning foxglove as a novel raw material for pharmaceutical applications (J Pharm Biomed Anal, PMID 32980793). Bansal et al. (2022) assessed ploidy status and nuclear DNA content in Digitalis purpurea regenerated in vitro, providing critical genomic data for standardizing cardiac glycoside production from foxglove tissue cultures (Genes, PMID 36553602). Verma et al. (2016) successfully demonstrated somatic embryogenesis and pigment accumulation in Digitalis davisiana, advancing biotechnological methods for sustainable production of foxglove-derived bioactive compounds (Indian J Exp Biol, PMID 27295921). Hwang (2009) reported catalpol production in Chinese foxglove (Rehmannia glutinosa) hairy roots transformed with Agrobacterium rhizogenes, highlighting biotechnological routes for iridoid glycoside production from the related Rehmannia species (Methods Mol Biol, PMID 19521851).
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Primary Bioactives (Highly Toxic): Cardiac glycosides (Digitoxin, Digoxin) – potent cardiotonic agents. - Other Compounds: Flavonoids (antioxidant support), Saponins (potential diuretic effects). - Critical Note: The concentration of these compounds makes the raw plant highly toxic and unsuitable for any non-pharmaceutical application.
Reported Mechanism (Provisional)
The primary bioactive cardiac glycosides in foxglove root—digitoxin and digoxin—selectively bind to the α-subunit of the sodium-potassium ATPase (Na+/K+-ATPase) enzyme on cardiac myocyte cell membranes, inhibiting its function and elevating intracellular sodium concentration. This sodium accumulation reverses the sodium-calcium exchanger (NCX), leading to increased intracellular calcium availability, which enhances actin-myosin cross-bridge formation and produces a positive inotropic effect (stronger myocardial contractions). Additionally, these glycosides exert vagomimetic effects on the atrioventricular (AV) node, prolonging the refractory period and slowing conduction velocity, which accounts for their negative chronotropic and antiarrhythmic actions. Beyond cardiac glycosides, Zengin et al. (2020, PMID 32980793) identified phenolic and flavonoid constituents in Digitalis cariensis that inhibit cholinesterases and tyrosinase through competitive and non-competitive binding, suggesting secondary neuropharmacological and dermatological mechanisms.
Clinical Narrative (Provisional)
Extensive clinical research has established the efficacy of purified foxglove glycosides in cardiovascular medicine, with digoxin being one of the most thoroughly studied cardiac medications. Multiple randomized controlled trials, including the landmark DIG trial with over 6,800 participants, have demonstrated digoxin's ability to improve symptoms and reduce hospitalizations in heart failure patients. Clinical studies consistently show these compounds' effectiveness in controlling ventricular rate in atrial fibrillation, though therapeutic drug monitoring is essential due to the narrow margin between therapeutic and toxic doses. The evidence base spans decades of clinical use with well-documented pharmacokinetic and pharmacodynamic profiles.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.